Boehringer Ingelheim has opened another front in its attack on chronic kidney disease (CKD), offering Rectify Pharmaceuticals up to $448 million to partner on a preclinical program. The alliance ...
Writer’s Prelude. Today I write with a heavy heart but one which has potentially too much to say, so bear with me as I jump from several topics. This DT will likely be long and it likely won’t be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback